The highly anticipated Retatrutide 20mg device, a novel dual GIP and GLP-1 receptor , is currently being assessed by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. General availability https://buyretatrutideweightloss.co.uk/product/alluvi-tirzepatide-40mg/